BioMerieux snares stake in Knome

France's BioMerieux has acquired a 10 percent stake in Knome for $5 million and struck a deal to use the Cambridge, MA-based company's genome sequencing and analysis services. "The deal with Knome allows the group to strengthen its position in molecular biology and to create diagnostic tools for tomorrow," CM-CIC Securities analyst Arsene Guekam said in a research note. Story

Suggested Articles

A phase 1/2b test showed Roche's antibody mosunetuzumab can trigger durable responses in a significant minority of hard-to-treat NHL patients.

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.